Clinical Trials for COPD
Chronic obstructive pulmonary disease (COPD) is a progressive respiratory condition that affects millions of people worldwide. Current treatments help manage COPD symptoms, but many adult COPD patients still experience exacerbations and declining pulmonary function amid disease progression. COPD clinical trials are helping to advance available treatment options and drive better outcomes.
RDI’s experience in COPD clinical studies
With over 30 years of experience, Remington-Davis (RDI) is a trusted leader in COPD clinical research. As a research site and clinical trial management partner, we have successfully conducted 100+ COPD clinical trials, working closely with sponsors, CROs, and investigators to manage high-quality studies that fuel advancement.
Each study is led by an experienced principal investigator with deep expertise in pulmonary function and respiratory medicine, ensuring patients receive rigorous, expert oversight throughout their participation.
Backed by a patient-centric approach, we strive to make trial participation as comfortable and as convenient as possible. We offer flexible scheduling, transportation services, and a 7,500 square-foot facility equipped with at-home amenities like Wi-Fi, beverages, snacks, and more. It's variables like these that help us maintain a 97% patient retention rate.
At RDI, we are committed to advancing COPD research while fostering a supportive, patient-centered experience—because better trials mean better treatments for everyone. Be a part of our next medical breakthrough.
Frequently asked questions about clinical trials for COPD
Not all COPD clinical trials use a placebo-controlled study design. Some studies look at medications as add-on treatments and therapy. Many studies use a randomized controlled trial format, which means participants are randomly assigned to receive either the investigational treatment or a comparator, but the approach varies. Some trials compare a new treatment to a standard therapy, while others evaluate different drug combinations or disease management strategies. The type of study depends on the primary objective of the research study.
COPD clinical trials progress through four phases to evaluate a treatment’s efficacy and safety, as well as its long-term impact. Phase I trials are small studies focused on determining a new drug’s safety, dosage, and potential side effects in humans. Phase II is where researchers assess its effectiveness and optimal dosing in a larger group of participants. Phase III studies are large-scale studies involving hundreds to thousands of COPD patients, comparing the investigational treatment to standard therapies or a placebo. Phase IV studies continue to track long-term safety and effectiveness in a broader population.
In clinical trials, efficacy is typically measured by looking at things like how often a participant experiences exacerbations, changes in lung function (often tested through a simple breathing test called spirometry), ability to exercise or perform daily physical activities, and how symptoms affect quality of life and overall well-being. Researchers track these health status measures over time to understand whether the investigational treatment is making a meaningful difference.
It depends on the specific study. Some trials are designed specifically for adult COPD patients who have experienced recent or frequent exacerbations, while others may require a stable period before enrollment. Our team will review a participant's full medical history during the screening process to determine which studies they may be eligible for.
